Juan Andres - 01 Jul 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
01 Jul 2022
Net transactions value
-$774,420
Form type
4
Filing time
05 Jul 2022, 16:59:03 UTC
Previous filing
13 Jun 2022
Next filing
08 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $41,860 +2,000 +19% $20.93* 12,367 01 Jul 2022 Direct F1
transaction MRNA Common Stock Options Exercise $41,860 +2,000 +16% $20.93* 14,367 01 Jul 2022 Direct F1
transaction MRNA Common Stock Options Exercise $41,860 +2,000 +14% $20.93* 16,367 01 Jul 2022 Direct F1
transaction MRNA Common Stock Sale $900,000 -6,000 -37% $150.00 10,367 01 Jul 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -2,000 -0.82% $0.000000 243,025 01 Jul 2022 Common Stock 2,000 $20.93 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -2,000 -0.82% $0.000000 241,025 01 Jul 2022 Common Stock 2,000 $20.93 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -2,000 -0.83% $0.000000 239,025 01 Jul 2022 Common Stock 2,000 $20.93 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.
F2 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer